#1 Clinical Trials Search in Europe

Cobolimab

Cobolimab is an innovative drug currently being studied in clinical trials for its potential in treating various types of cancer. This article will provide an overview of the ongoing research, highlighting the drug’s mechanism, its combination with other treatments, and the promising results observed so far in different cancer types.

Table of Contents

What is Cobolimab?

Cobolimab is a new drug being developed for cancer treatment. It is also known by other names such as TSR-022 and GSK4069889A[2]. Cobolimab is a type of drug called a monoclonal antibody. Monoclonal antibodies are laboratory-made proteins that act like human antibodies in the immune system. They are designed to recognize and attach to specific proteins or cells in the body[2].

How Does Cobolimab Work?

Cobolimab is specifically designed to target a protein called TIM-3 (T cell immunoglobulin and mucin domain-containing protein 3). TIM-3 is found on certain immune cells and can sometimes prevent these cells from effectively fighting cancer. By blocking TIM-3, cobolimab aims to boost the immune system’s ability to recognize and attack cancer cells[2].

What Conditions Does Cobolimab Treat?

Cobolimab is being studied for the treatment of various types of cancer, including:

  • Advanced solid tumors: These are cancers that form solid masses in the body and have spread or are in an advanced stage[1].
  • Cervical cancer: Specifically, cobolimab is being tested in patients with advanced, metastatic (spread to other parts of the body), or recurrent (returned after initial treatment) cervical cancer[2].
  • Melanoma: This is a type of skin cancer[1].

Clinical Trials and Research

Cobolimab is currently being studied in several clinical trials to determine its safety and effectiveness. These trials are testing cobolimab in different ways:

  • As a single treatment: Some studies are looking at how well cobolimab works on its own[1].
  • In combination with other drugs: Many trials are testing cobolimab together with other cancer treatments. For example:
    • Cobolimab is being studied in combination with a drug called dostarlimab in patients with cervical cancer[2].
    • Another study is looking at cobolimab combined with dostarlimab and a third drug called feladilimab (GSK3359609) in patients with various types of advanced solid tumors[4].
  • In different patient groups: Some studies are focusing on specific groups, such as children and young adults with cancer[1].

These clinical trials are designed to answer important questions about cobolimab, such as:

  • What is the safest and most effective dose?
  • How well does it work against different types of cancer?
  • What are the side effects?
  • How does it interact with other cancer treatments?

Potential Side Effects

As cobolimab is still in the research phase, all of its potential side effects are not yet known. The clinical trials are carefully monitoring patients for any adverse events (side effects). Some of the things researchers are watching for include:

  • Immune-related side effects: Since cobolimab works by affecting the immune system, there’s a possibility it could cause the immune system to attack healthy cells in the body[1].
  • Changes in laboratory tests: Researchers are checking if cobolimab affects things like blood cell counts or liver function tests[1].
  • Effects on vital signs: This includes monitoring for any changes in heart rate, blood pressure, or body temperature[1].

It’s important to note that in clinical trials, any side effects are closely monitored and managed by healthcare professionals.

Future Prospects

While cobolimab shows promise, it’s important to remember that it is still an experimental drug. The U.S. Food and Drug Administration (FDA) has not yet approved cobolimab for general use[2]. However, the ongoing research is helping to determine if cobolimab could become a valuable new tool in cancer treatment.

If the clinical trials show positive results, cobolimab could potentially offer new hope for patients with advanced cancers, especially those who haven’t responded well to other treatments. As research continues, we’ll learn more about how effective and safe cobolimab is, and which patients might benefit most from this new therapy.

Aspect Details
Drug Type Monoclonal antibody targeting TIM-3
Administration Intravenous infusion
Cancer Types Studied Melanoma, cervical cancer, advanced solid tumors
Combination Therapies Dostarlimab, pembrolizumab, various chemotherapy regimens
Key Outcomes Measured Safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity
Trial Phases Phase 1/2 studies
Notable Features Being studied in both adult and pediatric populations

FAQ

  • What is Cobolimab? Cobolimab is a type of drug called a monoclonal antibody. It's designed to target a specific protein in the body called TIM-3, which is involved in regulating the immune system's response to cancer cells.
  • What types of cancer is Cobolimab being tested for? Cobolimab is being studied in clinical trials for various types of cancer, including melanoma, cervical cancer, and other advanced solid tumors.
  • How is Cobolimab administered? Cobolimab is given as an intravenous (IV) infusion, which means it's delivered directly into the bloodstream through a vein.
  • Is Cobolimab used alone or with other treatments? Cobolimab is being tested both as a standalone treatment and in combination with other cancer drugs, such as dostarlimab, pembrolizumab, and various chemotherapy regimens.
  • What are the potential side effects of Cobolimab? As with any drug in clinical trials, the full range of side effects is still being studied. Researchers are closely monitoring for any adverse events, which may include immune-related side effects. The specific side effects will be better understood as more data from the trials becomes available.

Ongoing Clinical Trials on Cobolimab

  • Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Finland France Germany Greece Italy +5

  • Study of Cobolimab and Dostarlimab for Children and Young Adults with Newly Diagnosed or Relapsed/Refractory Tumors

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Italy Spain

Glossary

  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. In cancer treatment, monoclonal antibodies can be used to carry drugs, toxins, or radioactive substances directly to cancer cells.
  • TIM-3: T cell immunoglobulin and mucin domain-containing protein 3, a protein involved in regulating immune responses. It's a target for some cancer immunotherapies.
  • Intravenous infusion: A method of delivering medications directly into the bloodstream through a vein.
  • Dostarlimab: Another type of monoclonal antibody used in cancer treatment, often studied in combination with Cobolimab.
  • Solid tumors: Abnormal masses of tissue that usually do not contain cysts or liquid areas. Solid tumors may be benign or malignant.
  • Immune-mediated adverse events: Side effects caused by the activation of the immune system in response to treatment.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body.
  • Dose-limiting toxicity: Side effects of a drug that are severe enough to prevent an increase in dose or require a decrease in dose.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.

References

  1. https://clinicaltrials.gov/study/NCT06521567
  2. https://clinicaltrials.gov/study/NCT06238635
  3. https://clinicaltrials.gov/study/NCT04446351
  4. https://clinicaltrials.gov/study/NCT02723955